L-Carnosine and Reduced Obsessive-Compulsive Symptoms

• Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis.

  • 2021-11-04
  • Meta-Analysis · n = 759
  • BMC pharmacology & toxicology 22(1)
  • • Fatemeh Hadi
    • Shayan Kashefinejad
    • Leila Kamalzadeh
    • Saba Hoobehfekr
    • Mohammadreza Shalbafan

  • PubMed: 34736541
  • DOI: 10.1186/s40360-021-00534-6

  1 Insight on

  • Reduced Obsessive-Compulsive Symptoms

  • High evidence
  • Clinical

  Glutamaterigic drug plus SSRIs were superior to SSRI+ Placebo with regard to Y-BOCS scale [standardized mean difference (SMD = - 3.81 95% CI = - 4.4, - 3.23).

  Effect

  Beneficial

  Effect size

  Large

  Significant

  Yes

• L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study.

  • 2017-05-08
  • RCT
  • Human psychopharmacology 32(4)
  • • Somaye Arabzadeh
    • Maryam Shahhossenie
    • Bita Mesgarpour
    • Farzin Rezaei
    • Mohammad Reza Shalbafan
    • Zahra Ghiasi
    • Shahin Akhondzadeh

  • PubMed: 28485008
  • DOI: 10.1002/hup.2584

  1 Insight on

  • Reduced Obsessive-Compulsive Symptoms

  • High evidence
  • Clinical

  General linear model repeated measure showed significant effects for Time × Treatment interaction on total Y-BOCS [F (2.10, 88.42) = 8.66, p < 0.001], obsession [F (1.88, 79.34) = 4.96, p = 0.01] and compulsion [F (1.88, 79.11) = 4.57, p = 0.01]. At week 10, the change from baseline in Y-BOCS scores was 8.86 ± 2.89 (mean ± SD) in the L-carnosine group compared to 5.86 ± 2.88 in the placebo group.

  Effect

  Beneficial

  Effect size

  Moderate

  Significant

  Yes

  Dose

  not stated